PFE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pfizer Inc (PFE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock offers a high dividend yield and has positive news regarding its obesity drug approval in China, the company's financial performance is weak, and technical indicators suggest a bearish trend. Analyst ratings are mixed, with significant concerns about revenue declines and loss of exclusivity for key drugs. Given the investor's preference for long-term growth, it would be prudent to wait for clearer signs of recovery or stronger growth catalysts before investing.
The MACD is negatively expanding (-0.127), indicating bearish momentum. RSI is at 36.789, suggesting the stock is approaching oversold territory but not yet at a buy signal. Moving averages are converging, showing indecision. Key support is at $26.387, with resistance at $27.51. Pre-market price is $26.44, slightly above support, but the overall trend is bearish with a potential for further downside (-1.48% next day, -4% next week, -8.46% next month).
China's approval of Pfizer's obesity drug Ecnoglutide expands its market presence. The company's dividend yield of 6.3% is attractive for income-focused investors. Argus upgraded the stock to Buy with a $35 price target, citing confidence in its GLP-1 and oncology pipelines.
Weak financial performance in Q4 2025, with revenue down 1.16% YoY, net income down 501.95% YoY, and EPS down 514.29% YoY. Analysts have expressed concerns about revenue cliffs from loss of exclusivity for key drugs, with no near-term catalysts to offset these losses. Technical indicators suggest a bearish trend, and stock trend analysis predicts further downside in the short term.
In Q4 2025, revenue decreased by 1.16% YoY to $17.56 billion. Net income dropped significantly to -$1.65 billion, a decline of 501.95% YoY. EPS fell to -$0.29, down 514.29% YoY. However, gross margin improved to 64.15%, up 6% YoY, indicating some operational efficiency improvements.
Analyst ratings are mixed. Argus recently upgraded the stock to Buy with a $35 price target, citing confidence in its pipeline. However, RBC Capital and Barclays initiated coverage with Underperform and Underweight ratings, respectively, citing revenue cliffs and lack of near-term catalysts. The average price target ranges between $25 and $35, reflecting uncertainty in the stock's near-term performance.
